Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07483073 | A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease | PHASE2 | RECRUITING | 60 | — | — | May 4, 2026 | Mar 1, 2028 | Jun 4, 2026 | 72 | United States, Belgium +8 |
| Arm | Type | Description |
|---|---|---|
| Mirikizumab | ACTIVE_COMPARATOR | Study Period 1: mirikizumab administered via IV. Study Period 2: Responders will receive mirikizumab SC. |
| LY4395089 and Mirikizumab Co-Administration | EXPERIMENTAL | Study Period 1: Co-administration of LY4395089 administered orally and mirikizumab administered IV. Study Period 2: Responders will stop LY4395089 and receive mirikizumab SC. |
| Name | Type | Description |
|---|---|---|
| Mirikizumab - Intravenous (IV) | DRUG | Administered IV |
| Mirikizumab - Subcutaneous (SC) | DRUG | Administered SC |
| LY4395089 | DRUG | Administered orally |
Inclusion Criteria: * Must have an established diagnosis of Ulcerative Colitis (UC) or Crohn's Disease (CD) for at least 3 month duration, which includes clinical and endoscopic evidence of UC or CD and a histopathology report that supports a diagnosis of UC or CD. * For UC: * Have moderately to...